Ampio Pharmaceuticals (OTCPK:AMPE) - Hisse Senedi Fiyatı, Haberler ve Analizler

AMPE Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan Ampio Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde diz osteoartriti (OAK) tedavisi için tedaviler geliştirmektedir. Daha fazla detay

AMPE temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Kazançlar son 5 yılda yılda 28.4% oranında azaldı

Anlamlı bir piyasa değeri yok ( $85K )

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 2 daha fazla risk

Ampio Pharmaceuticals, Inc. Rakipler

Veritas Farms

OTCPK:VFRM

US$81.9k

CBD Life Sciences

OTCPK:CBDL

US$1.4m

Hero Technologies

OTCPK:HENC

US$563.0

Kid Castle Educational

OTCPK:KDCE

US$357.2k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Ampio Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.0026
52 Haftanın En Yüksek Seviyesi	US$7.47
52 Haftanın En Düşük Seviyesi	US$0.000001
Beta	3.71
11 Aylık Değişim	18.18%
3 Aylık Değişim	18.18%
1 Yıllık Değişim	-99.87%
33 Yıllık Değişim	-100.00%
5 Yıllık Değişim	-100.00%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Here's Why We're Watching Ampio Pharmaceuticals' (NYSEMKT:AMPE) Cash Burn Situation

Feb 17

Hissedar Getirileri

	AMPE	US Pharmaceuticals	US Pazar
7D	-74.0%	3.4%	1.6%
1Y	-99.9%	14.2%	32.3%

Getiri vs. Endüstri: AMPE geçen yıl % 14.2 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: AMPE geçen yıl % 32.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is AMPE's price volatile compared to industry and market?
AMPE volatility
AMPE Average Weekly Movement	324.1%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: AMPE hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: AMPE 'nin haftalık oynaklığı son bir yılda 1564% dan 324% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	6	Mike Martino	ampiopharma.com

Bir biyofarmasötik şirketi olan Ampio Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde diz osteoartriti (OAK) tedavisi için tedaviler geliştirmektedir. Şirket, OAK ağrısının tedavisi için küçük moleküllü bir formülasyon olan OA-201'i geliştirmektedir. Ampio Pharmaceuticals, Inc. şirketinin merkezi Englewood, Colorado'da bulunmaktadır.

Ampio Pharmaceuticals, Inc. Temel Bilgiler Özeti

Ampio Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
AMPE temel i̇stati̇sti̇kler
Piyasa değeri	US$85.27k
Kazançlar(TTM)	-US$8.63m
Gelir(TTM)	n/a

0.0x

P/S Oranı

0.0x

F/K Oranı

AMPE aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
AMPE gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$8.63m
Kazançlar	-US$8.63m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-7.60
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	5.3%

AMPE uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

AMPE Stoklara Genel Bakış

Risk Analizi

Ampio Pharmaceuticals, Inc. Rakipler

OTCPK:VFRM

US$81.9k

OTCPK:CBDL

US$1.4m

OTCPK:HENC

US$563.0

OTCPK:KDCE

US$357.2k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Price target decreased to US$3.50

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Chief Operating Officer exercised options and sold US$111k worth of stock

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

CFO, Corporate Secretary & Treasurer exercised options and sold US$56k worth of stock

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

CFO, Corporate Secretary & Treasurer exercised options to buy US$59k worth of stock.

Here's Why We're Watching Ampio Pharmaceuticals' (NYSEMKT:AMPE) Cash Burn Situation

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

New 90-day high: US$2.76

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: US$1.17

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - US$0.80

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Ampio Pharmaceuticals, Inc. Temel Bilgiler Özeti

0.0x

0.0x

Kazanç ve Gelir